TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
0.336
+0.008 (2.50%)
At close: Nov 20, 2024, 4:00 PM
0.329
-0.008 (-2.23%)
After-hours: Nov 20, 2024, 4:30 PM EST

TransCode Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Selling, General & Admin
5.227.158.43.40.440.23
Upgrade
Research & Development
9.4312.2610.232.750.280.23
Upgrade
Operating Expenses
14.6519.4218.636.150.730.46
Upgrade
Operating Income
-14.65-19.42-18.63-6.15-0.73-0.46
Upgrade
Interest Expense
-0.06-0.06-0.03-0.1-0.39-0.16
Upgrade
Interest & Investment Income
00.010.02000
Upgrade
Other Non Operating Income (Expenses)
0.070.921.08-0.59-1.220.01
Upgrade
EBT Excluding Unusual Items
-14.93-18.55-17.56-6.84-2.34-0.61
Upgrade
Gain (Loss) on Sale of Assets
----0--
Upgrade
Pretax Income
-14.93-18.55-17.56-6.84-2.34-0.61
Upgrade
Net Income
-14.93-18.55-17.56-6.84-2.34-0.61
Upgrade
Net Income to Common
-14.93-18.55-17.56-6.84-2.34-0.61
Upgrade
Shares Outstanding (Basic)
7000--
Upgrade
Shares Outstanding (Diluted)
7000--
Upgrade
Shares Change (YoY)
18942.25%1003.48%54.03%---
Upgrade
EPS (Basic)
-2.17-103.61-1082.79-649.77--
Upgrade
EPS (Diluted)
-2.17-103.61-1082.79-649.77--
Upgrade
Free Cash Flow
-15.87-18.11-15.86-5.52-0.49-0.51
Upgrade
Free Cash Flow Per Share
-2.31-101.17-977.90-524.28--
Upgrade
EBITDA
-14.54-19.3-18.54-6.11--
Upgrade
D&A For EBITDA
0.110.120.10.04--
Upgrade
EBIT
-14.65-19.42-18.63-6.15-0.73-0.46
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.